Not Yet RecruitingEarly Phase 1NCT07631299

Nebulized AER101 in Pre-op NSCLC

The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors. Participants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.

Checked against the public recordLast updated Jun 8, 2026 · Source: ClinicalTrials.gov

StatusNot Yet Recruiting
PhaseEarly Phase 1
U.S. locations2
SponsorUniversity of Oklahoma
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Early Phase 1
Sponsor
University of Oklahoma
Interventions being studied
Drug: AER101
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * 18 years or older * Agree to sign consent and follow study requirements * Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma * Primary patients prior to resection * Candidate for surgery (patients are qualified for inclusion if surgery or radiation treatment are agreed to) * Baseline PET/CT imaging performed at Stephenson Cancer Center available and performed within previous 30 days Exclusion Criteria: * Recurrent tumor(s) * Nodal or metastatic tumor (multiple lung tumors are acceptable) * Pregnant patients * Patients unable to provide informed consent * Prisoners

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • OU Medical Center HospitalOklahoma City, Oklahoma
  • Stephenson Cancer CenterOklahoma City, Oklahoma

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 8, 2026. Always confirm current availability with the study team.

View original record ↗